Open access
Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions
Medicine
Abstract
may assist pseudoprogression interpretation, while RECIST maintains superiority in standardization, regulatory acceptance, and spatial resolution. Based on these complementary characteristics, we propose a ctDNA-enhanced RECIST framework (C) , in which ctDNA serves as an adjunct across three clinical scenarios: early ef fi cacy screening, iuPD decision-making, and treatment duration optimization.